Enliven Therapeutics (US.ELVN)
Capital Allocation Audit · Period: 2020 – 2026
Key Metrics
US.ELVN · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -5.2% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.00 | ↑ |
| Gross Margin | - | → |
US.ELVN (Enliven Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -5.2% ↑ Cash Conversion - → D/E Ratio 0.00 ↑ Gross Margin - →
Key Metrics
US.ELVN (Enliven Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -5.2% ↑Cash Conversion - →D/E Ratio 0.00 ↑Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies